- Home
- PROP vs APLT Comparison
PROP vs APLT Comparison
Compare PROP & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROP
- APLT
- Stock Information
- Founded
- PROP 2001
- APLT 2016
- Country
- PROP United States
- APLT United States
- Employees
- PROP N/A
- APLT N/A
- Industry
- PROP Investment Bankers/Brokers/Service
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- PROP Finance
- APLT Health Care
- Exchange
- PROP Nasdaq
- APLT Nasdaq
- Market Cap
- PROP 115.3M
- APLT 128.0M
- IPO Year
- PROP N/A
- APLT 2019
- Fundamental
- Price
- PROP $7.51
- APLT $0.65
- Analyst Decision
- PROP
- APLT Buy
- Analyst Count
- PROP 0
- APLT 7
- Target Price
- PROP N/A
- APLT $6.10
- AVG Volume (30 Days)
- PROP 261.1K
- APLT 7.5M
- Earning Date
- PROP 01-01-0001
- APLT 03-05-2025
- Dividend Yield
- PROP N/A
- APLT N/A
- EPS Growth
- PROP N/A
- APLT N/A
- EPS
- PROP N/A
- APLT N/A
- Revenue
- PROP $1,545,792.00
- APLT N/A
- Revenue This Year
- PROP $5,586.66
- APLT N/A
- Revenue Next Year
- PROP $244.90
- APLT $2,622.90
- P/E Ratio
- PROP N/A
- APLT N/A
- Revenue Growth
- PROP N/A
- APLT N/A
- 52 Week Low
- PROP $4.91
- APLT $0.60
- 52 Week High
- PROP $16.08
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- PROP 53.17
- APLT 20.60
- Support Level
- PROP $4.91
- APLT $0.60
- Resistance Level
- PROP $7.25
- APLT $0.74
- Average True Range (ATR)
- PROP 0.79
- APLT 0.09
- MACD
- PROP 0.13
- APLT 0.21
- Stochastic Oscillator
- PROP 77.61
- APLT 13.53
About PROP Prairie Operating Co.
Prairie Operating Co develops and operates bitcoin mining scaled-up facilities using natural gas to power the operations. It generates substantially all its revenue through cryptocurrency, which it earns through mining activities.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.